tldrdaily.news logo
Tag

Astellas

All articles tagged with #astellas

Astellas and Vir Strike Global Deal to Advance VIR-5500 for Prostate Cancer
business2 days ago

Astellas and Vir Strike Global Deal to Advance VIR-5500 for Prostate Cancer

Astellas and Vir Biotechnology announced a global strategic collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer; U.S. commercialization led by Astellas (Vir may co-promote), ex-U.S. commercialization to Astellas, development costs shared 60/40 (Astellas/Vir), Vir to receive $335 million upfront/near-term payments and up to $1.37 billion in milestones, with royalties on ex-U.S. net sales and a potential 50/50 U.S. profit/loss share if Vir elects to co-promote; closing subject to customary regulatory clearances.

via Vir Biotechnology|
#astellas#business#prostate-cancer
Astellas partners with biotech startup for safer gene therapy treatment of neuromuscular condition.
healthcare2 years ago

Astellas partners with biotech startup for safer gene therapy treatment of neuromuscular condition.

Astellas is partnering with startup Kate Therapeutics to revisit X-linked myotubular myopathy, a fatal neuromuscular condition for which there are currently no treatments. The move comes four years after Audentes Therapeutics presented powerful data on a young boy with the condition at a cell and gene therapy conference.

via Endpoints News|
#astellas#audentes-therapeutics#gene-therapy
Japanese Pharma Giants Make Bold Moves in M&A and Drug Development
pharmaceuticals2 years ago

Japanese Pharma Giants Make Bold Moves in M&A and Drug Development

Johnson & Johnson has paid $245m upfront for global development and commercialisation rights to two early-stage, autologous CAR-T therapy programmes from CBMG, which has a track record of allying itself with the biggest names in the development world. Astellas Pharma is to buy Iveric Bio for $5.9bn in cash, while Pfizer is focusing on M&A and oncology as Covid sales decline. The US government's court battle has begun over Gilead HIV drug patents, while Boehringer Ingelheim is to construct a $300m+ facility at its HQ. Sanofi is using its sponsorship of the Paris Olympics to encourage employees to find their potential, while Novo Nordisk is teaming up with a professional soccer player living with type 1 diabetes to highlight the possibilities of a life with the chronic disease.

via Endpoints News|
#astellas#car-t-therapy#cbmg
Xtandi drug combo reduces risk of prostate cancer metastasis and death.
healthcare2 years ago

Xtandi drug combo reduces risk of prostate cancer metastasis and death.

Pfizer and Astellas have reported that their drug Xtandi, in combination with leuprolide, reduces the risk of metastasis and death in prostate cancer by 58%. The Phase III EMBARK trial tested Xtandi plus leuprolide and Xtandi as a monotherapy against placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. The companies believe that the data shows the potential for Xtandi to be added to the standard of care if a label expansion is approved.

via Endpoints News|
#astellas#clinical-trial#drug-combination
US Government Rejects Attempts to Lower Price of Cancer Drug Xtandi.
healthcare2 years ago

US Government Rejects Attempts to Lower Price of Cancer Drug Xtandi.

The National Institutes of Health has declined to use "march-in" rights to lower the price of Astellas and Pfizer's prostate cancer drug Xtandi despite being invented at UCLA with grants from the US Army and NIH. The institutes' analyses found Xtandi "to be widely available to the public," an indication that there was not a pressing need for the US to act. Under the Bayh-Dole Act, the government can promote the commercialization and public availability of even partially government-funded inventions, but the move has never been successful.

via Endpoints News|
#astellas#bayh-dole-act#drug-pricing